Search the Newsreel

Foresight Autonomous (FRSX) shareholders approve agenda items, reject Proposal No. 6

Foresight Autonomous Holdings Ltd. (FRSX) shareholders approved all but one agenda item, Proposal No. 6, at their Annual and Extraordinary General Meeting held on July 23, 2026. The outcomes of the meeting, as detailed in the proxy statement, are now incorporated by reference into …

Insight Enterprises Inc (NSIT) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Insight Enterprises Inc (NSIT), identifying its major institutional holders such as BlackRock, Vanguard, and Fidelity. It breaks down shareholder types by proportion, providing insights into the institutional ownership landscape. The report also includes historical institutional shareholding data …

Insight Enterprises Inc (NSIT) Earnings Forecast: Future EPS & Revenue Growth Estimates

The article provides an earnings forecast for Insight Enterprises Inc (NSIT), highlighting its current earnings forecast score of 7.50 and ranking within the Software & IT Services industry. It details analyst ratings, target prices, and expected future revenue and EPS, indicating a general "Buy" …

IMDX|Insight Molecular Diagnostics Ord Shs|Price:4.960|Chg%:-0.030

This page provides a detailed overview of Insight Molecular Diagnostics Ord Shs (IMDX), including its current stock price, key financial figures, and recent performance. The company's stock closed at $4.730, experiencing a 4.64% decrease. Analyst ratings suggest a "Buy" with a significant upside, despite …

Medicare coverage confirmed for iMDx kidney-rejection monitoring test

Insight Molecular Diagnostics (iMDx) announced that a new Lancet study demonstrated its GraftAssure donor-derived cell-free DNA (dd-cfDNA) assay could guide treatment for antibody-mediated rejection in kidney transplant patients, potentially reducing drug use by two-thirds. The company also confirmed Medicare reimbursement coverage from MolDX for …

KEYS|Keysight Technologies Inc|Price:325.115|Chg%:-2.415

Keysight Technologies Inc. (KEYS) is highlighted as having very healthy fundamentals and high growth potential, with its valuation considered fairly valued. Despite recent weak stock market performance, the company shows strong underlying fundamentals and is rated "Buy" by analysts with a target price of …

Keysight Technologies stock holds near recent range as investors weigh latest earnings and test equi

Keysight Technologies stock is trading in a stable range as investors evaluate its fiscal Q2 2024 earnings, where revenue declined year-over-year but operating margins remained resilient. The company generated approximately $1.2 billion in revenue and sustained operating margins in the mid-twenty percent range, indicating …

3 Stocks That Might Be Trading Below Their Estimated Intrinsic Values

This article identifies three U.S. stocks—Insight Enterprises (NSIT), Ouster (OUST), and Prosperity Bancshares (PB)—that are trading below their estimated intrinsic values based on future cash flows. Despite various market conditions and challenges, all three companies show promising earnings growth forecasts and strategic initiatives that …

What to Expect From Keysight Technologies' Q3 2026 Earnings Report

Foresight Autonomous Holders Shareholders Approve Most Proposals at July 23 Meeting

Foresight Autonomous Holdings (FRSX) announced that shareholders approved most proposals at their Annual and Extraordinary General Meeting held on July 23, 2026, with only Proposal No. 6 not passing. The outcomes will influence the company's future governance and capital market activities, with the report …

J.P. Morgan Maintains Insight Enterprises(NSIT.US) With Hold Rating, Raises Target Price to $135

J.P. Morgan has reiterated its Hold rating on Insight Enterprises (NSIT.US) and increased its price target to $135. This indicates a continued cautious but slightly more optimistic outlook on the company's stock from the analyst.

Keysight Technologies (KEYS) Lands ESA Collaboration, Is The Stock A Bargain?

Keysight Technologies (KEYS) has secured a significant three-year collaboration with the European Space Agency (ESA) to develop blockchain-based anomaly detection for 5G and 6G satellite connectivity, bolstering its position in secure non-terrestrial networks. Despite a recent share price pullback, strong year-to-date and one-year returns, …

NSIT5813006 Bond Profile — Key Metrics

This article provides a detailed profile of the NSIT5813006 bond issued by Insight Enterprises, Inc. Key metrics such as the issue date, maturity date, outstanding amount, face value, and coupon rate are highlighted. The bond, maturing on May 15, 2032, has a 6.63% coupon …

NSIT5813006 Bond Risk Profile

This article provides a bond risk profile for NSIT5813006, an Insight Enterprises, Inc. bond with a 6.625% coupon maturing on May 15, 2032. It highlights key metrics for credit risk assessment, including security level, inflation protection, and issuer rating, to help investors make informed …

Sight Sciences schedules results webcast for Aug. 5 at 4:30 p.m. ET

Sight Sciences (Nasdaq: SGHT) announced it will report its second-quarter 2026 financial results after market close on Wednesday, August 5, 2026. Management will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET, accessible via live and archived webcast on the Investors …

Will Insight Enterprises (NSIT) Beat Estimates Again in Its Next Earnings Report?

If you are looking for a stock that has a solid history of beating earnings estimates and is in a good position to maintain the trend in its next quarterly report, you should consider Insight Enterprises (NSIT). This company, which is in the Zacks …

Elsight Achieves Record H1 2026 Revenue of US$23.4 Million as Defence Contracts and Global Expansion Drive Profitability

Elsight (ASX:ELS) Reports Record H1 Revenue as Global Defence Footprint Expands

Elsight Limited (ASX:ELS): Why the Drone Connectivity Play Is Commanding Attention

Sight Sciences to Report Second Quarter 2026 Financial Results on August 5, 2026

Sight Sciences, Inc. (NASDAQ: SGHT) is scheduled to release its financial results for the second quarter of 2026 on August 5, 2026. The company will host a conference call and webcast on the same day to discuss the results and provide a business update. …

KEY stock holds on Keysight revenue and EPS context

This article focuses on how Keysight Technologies Inc.'s fiscal 2025 financial results, including revenue of $3.99 billion and diluted EPS of $4.94, provide context for the KEY stock. It highlights the company's annual growth and increased earnings per share as key metrics for investors …

Keysight Tool Simulates Drop, Shock and Vibration Before Prototypes

Keysight Technologies (NYSE: KEYS) has launched Keysight Multiphysics, a new design and verification solution that addresses cross-domain physics issues in electronic designs to prevent late-stage failures. The initial application focuses on structural analysis for drop, shock, and vibration, allowing engineers to identify and fix …

Insight Enterprises Inc. (IEI) Q3 2024 Earnings Report - Results, Call & Slides

Insight Enterprises Inc. (IEI) reported its Q3 2024 earnings, missing both EPS and revenue expectations. The company recorded an actual EPS of €1.92 against a consensus of €2.02, and actual revenue of €1.83B compared to an expected €1.96B, marking a year-over-year revenue decline of …

Keysight Technologies stock trades steady as test and measurement leader digests recent earnings and

Keysight Technologies stock is trading steadily as the company digests its recent earnings report for fiscal Q2 2025, which showed resilient demand from aerospace, defense, and semiconductor customers, offsetting softness in some communications segments. The company's revenue and operating margins remained strong, driven by …

Press Release: Insight Enterprises, Inc. to Report Second Quarter 2026 Financial Results on August 6, 2026

Insight Enterprises, Inc. (NASDAQ: NSIT) announced it will report its second quarter 2026 financial results on Thursday, August 6, 2026. The company will also host a conference call and live webcast to discuss these results.

Enterprise value to revenue forward of Insight Molecular Diagnostics Inc. – NASDAQ:IMDX

This article provides financial information for Insight Molecular Diagnostics Inc. (NASDAQ: IMDX), specifically focusing on its enterprise value to revenue forward. The content, sourced from TradingView, indicates a market closed status with no trades and highlights financial data from ICE Data Services and FactSet. …

Keysight Technologies stock steadies as investors weigh slower orders against recurring software gro

Keysight Technologies' stock is stabilizing as investors evaluate a balance between softening orders and a strong increase in recurring software and services revenue. The company is transitioning from a hardware vendor to a provider of integrated solutions, which includes subscriptions and technical services, aiming …

Sight Sciences wins $34M patent ruling against Alcon

Sight Sciences has won a $34 million patent infringement ruling against Alcon relating to its ophthalmic surgical devices used for glaucoma treatment. A jury in Delaware found that Alcon's Hydrus Microstent infringed on Sight Sciences' patents. Shares of Sight Sciences surged over 40% following …

Insight Enterprises Inc (NSIT) Stock Price & 30 Year Financial Data

This article provides comprehensive financial data for Insight Enterprises Inc (NSIT), including its current stock price, market capitalization, and various financial ratios like P/E and P/B. It also details growth rates for revenue, EPS, EBIT, EBITDA, and free cash flow over 1-year, 5-year, and …

BlackRock Portfolio Management (RXST) discloses 7.2% beneficial stake in RxSight

BlackRock Portfolio Management LLC has disclosed a 7.2% beneficial ownership stake in RxSight, Inc. (RXST), holding 2,982,816 shares as of June 30, 2026. The firm maintains sole voting power over 2,618,543 shares and sole dispositive power over all 2,982,816 shares, with no shared powers. …

Keysight Technologies Inc (KEYS) Stock Down 3.1% but Still Overvalued

Keysight Technologies Inc (KEYS) shares dropped 3.1% to $312.76, yet the stock is considered significantly overvalued with a GF Value™ of $200.70. Despite a strong GF Score™ of 82/100, driven by good financial strength, profitability, and growth, its valuation score is low due to …

Analysts Offer Insights on Healthcare Companies: RxSight (RXST), Kazia Therapeutics (KZIA) and Crescent Biopharma (CBIO)

Healthcare companies RxSight (RXST), Kazia Therapeutics (KZIA), and Crescent Biopharma (CBIO) have recently received analyst coverage. BTIG analysts offered ratings for RxSight and Kazia Therapeutics, while H.C. Wainwright provided an update for Crescent Biopharma. The article details analyst ratings, price targets, and consensus views …

JPMorgan Adjusts Price Target on Keysight Technologies to $400 From $390, Maintains Overweight Rating

JPMorgan has increased its price target for Keysight Technologies (NYSE:KEYS) to $400, up from the previous $390, while reiterating an Overweight rating on the stock. This adjustment suggests a continued positive outlook from the firm regarding Keysight Technologies' future performance.

RxSight (RXST) Surges 6.1%: Is This an Indication of Further Gains?

RxSight (RXST) shares increased by 6.1% to $5.57, driven by high trading volume and investor optimism regarding an upcoming leadership transition. Aziz Mottiwala is set to become the new President and CEO on July 20, 2026. Despite a projected quarterly loss of $0.21 per …

Insight Enterprises schedules before-market results and 9 a.m. call

Insight Enterprises, Inc. (Nasdaq: NSIT) announced it will release its second-quarter 2026 financial results prior to market open on August 6, 2026. The company will also host a conference call and live webcast at 9:00 a.m. ET on the same day to discuss the …

Medicare expands coverage for transplant monitoring test, boosting Insight Molecular Diagnostics' GraftAssure adoption.

Medicare has expanded its coverage for donor-derived cell-free DNA (dd-cfDNA) testing, which will increase patient access and testing frequency for kidney and heart transplant recipients. This policy change will benefit Insight Molecular Diagnostics (iMDx) and its GraftAssure transplant monitoring assays, supporting their strategy for …